Thyrocare Q1 FY27 Results: Revenue up 24%, PAT up 34% YoY
Thyrocare Technologies Limited reported Q1 FY27 consolidated revenue of ₹240 crore, up 24.3% YoY. PAT increased by 34.1% to ₹51.33 crore. Standalone revenue grew 26.1% to ₹225.66 crore, with PAT up 39.2% to ₹50.17 crore. Tests conducted rose 28% to 55.2 million, and active franchisees reached 11,730.
The results show significant financial growth and operational expansion, which are material to investors and the company's market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with positive operational metrics and industry recognition.
Thyrocare Technologies Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue of ₹240.02 crore, marking a 24.3% increase year-on-year (YoY). EBITDA saw a significant rise of 33.8% YoY, reaching ₹77.27 crore, with an improved EBITDA margin of 32.2%.
Profit After Tax (PAT) for the quarter grew by 34.1% YoY to ₹51.33 crore, with a PAT margin of 21.4%. Standalone revenue increased by 26.1% YoY to ₹225.66 crore, and standalone PAT jumped by 39.2% YoY to ₹50.17 crore. The company highlighted strong performance in its pathology business, with revenue up 27% YoY, while the radiology business saw a revenue decline of 4.0% YoY.
Key operational highlights include an increase in tests conducted to 55.2 million (+28% YoY) and a rise in patients served to 5.4 million (+17% YoY). The quarterly active franchisee count reached a new high of 11,730. The company also introduced new technology additions like Gut Microbiome and Whole Exome sequencing. Thyrocare was recognized with multiple awards, including 'Diagnostic Chain of the Year' and 'India's Most Trusted Customer-Focused Diagnostic Brand – 2026'. New laboratories were launched in Muzaffarpur, Prayagraj, and Kurnool to strengthen the testing network and improve turnaround times.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.